Cervical hematoma s are generally associated with trauma, surgery, and tum ors. Although they are rare, they can be life-threatening because they put the pati ent at risk fo rgreat-vessel compression and upper airway obstruction.
In adults and children ages 12 and older, the mo t commonly reported side effects were similar to vehicle placebo: ASACORT AQ 1 asal SprayIJS vehicle placebopharyngitis 5.1%/3.6%, epistaxis 2. %/0.8%, increase in cough 2.1%/ 1.5%; ASACORT 'asal InhalerIJS vehicle placebo-headache 18.0%/15.5%, nasal irritation 2.8%12.9%. Please --=u,n. t1J (triamcinolone acetonide)......"'" Forintranasal useon~. Shakel'lellBefere Using BRIEF SUMMARY C O NTRAINOICA TIONS Hypersensnivityto anyof the ingredientsof thispreparation Cllnlrai,dicates nsuse. WARNING S Thereplacementofasystemiccertlcesteroidwnh atopicalcorticosteroidcan be accompani edby si gnsofadrenalinsufficiency and,inaddITion, some patient smay experience symptemsolwnhdrawal; e.g.,jointandlor muscular pain,lassITudeand depression. Pa lientspr e l 1 ous~treated lor prolongedperiedswnh systemic certicestereidsandtransferredtotepical Cl l r t i c o~er o i d s sheuldbe ca r ef ul monrtored foraMe adrenal insufficiency inresponse tostress.Inthese patienlswho have aSIhmaorotherciinicalcondnions reQuiringleng-t erm systemlccortlcasterOId treatment, too rapid adecrease insystemic certicostereids may cause asevere exacerballon oftheirsymptoms. Children 1' ,tO are onimm unesuppressantdrugs are more suscept i b~toinf eclens tflan heallhychildren.C hickenpox and meas~s , forexamp~, can have amore senous oreven fatal Cl l u~e inchildren onimmunosuppressantdoses ofCllffiCllsleroids.Insuch children,er inadults who have not had tfl ese diseases,partICular care shouldbe takento aVlld exposure. II eXJlCS' d,tflernpy I ' , r~V" or i ce l l a-ze~er ",mune globuli n(\'ZIG)orpooled i ot rn l~nou s immunog boE n(MG ),as appropria:e,may be indcaled. lf ch~npox r?:e~ps , t'eZtmeot I' ,r.n anti' nral a~rr. s may be coosidered. PRE C AUTIONS G enera l:Incl inical studies with fnamcinoloneacelenide nasal spray,tfle develepmentof localizedinfectionsofItenose and pharynx with Candida albiCJns hasm r e~occurred.\'Ihen such an inf ectiondevelops nmayreQ uire treatmentW I Thappropnate local orsystemictherapy anddiscent inuanceoftreatmentI' ,itl Nasacort ADNasal Spray. Nasacort AD Ĩasa l Spray sheuld be usedv,ill! caution.ITat all ,inpatierr.s wnh acti;eer Q u~s ce n t tuberculousinfectioneltfl erespimtory tract orinpatientswnh untrealedf u ng~, bacterial, ersystemicvi ral infectienser ocular herpes simplex. Because01 the inhi brtoryeff ectofCllrticosteroids,inpatients who have experienced recent nasal sep~1 ulcers, nasal surgery,ortrauma,a corticost eroidshouldbe usedwithcaut ionuot ilhealing has occurred.As wrt hotfler nasa l~inhaledcorticosteroids,nasal septal perferations have been reported inrare instances. \'Ihen used at excessive deses,s~em i c c o r t i c o~e r e i d eHects such ashypercortic ism and adrenal suppressionmay appear. II such changes occur, Nasacort ADNasal Spmy shouldbe disconlinueds low~, consisteot wnh actepted procedures lor discootinuingami~er oi d Iherapy.
Infonnationlor Patients: P atientsbeingtreated with Nasacort AD Nasal Sprayshouldreceive tfle follOl' nngi n f erm~i on andinstruct lens.P~~nt s who areonim munosuppressant deses ef cer t i Cl l~er o i d s shouldbe v~med toavoidexposure to chic kenpoxer rreases and,I T exposed,toob~i n medicaladl 1ce. Patienlsshoulduse Nasaeort AD Nasal Sprayat regular intervalssince ilseffectiveness depends on ilS regular use. (See DOSAGE ANO AOMINISTRATION.) An im provementinsomepatieot symptems may be s~n Il 1tf1inthe firs1 day 01 treatment. and general~, I T~kes one week el treatmeot toreach maximum benef it Innialassessment forresponse should be made dunng tfl isti mefmme and pe r i l d i caJ~untithe patients symptoms are st ab~i zed . Thepatientshouldtakethemedicationas directed and shouldnotexceed tfl eprescnbed dosage.Thepatient should Cl l n~ct thephysician it symptems do nol improveafter threeweeks, orit thecondiliOnworsens. Paj entswho experience recurrenl episodesof e pistaxisInese bleeds)ernasal septum discomfort whilet a~ng thismedication shouldcontact theirphysician.Forthe proper use ofthi Sunrt and toaltam maximum improvement,the patientshould read and follew the acc ompan~n g patient instructionscar e f u l~. It isimportant toshake thebllttle wellbefere each use. Also, the boffleshould be discarded art er 120 actualionssince Ihe amount of triameinoloneacelonide delivered thereafterper actuationmay be s ubst a nt i a l~le ss thaD 55 m~01 drug_Do net transfer any remammg suspension toanolherborJe. C arcinogenesis, Mtrtagenesis. andImpairment of Fert ilITy:Inalila-year~udy inrats,tnamcinolone acetenidecaused no treatment-related carcinogenicity at oral doses up to1.0mcglkg{ a p p r ox i m a t e~1 130and 1150 ofthe maximum recommendeddailyiotranasaldose inadulls and children on amcg/rn' ba~s , r es peai v e~) . l n atva-year study inmice,~mci no l o ne aeetonide causednotreatmeot-rel2ted ca~i nogen i ci t y at oral doses up to3.0mcg~g l a p p r o xi m a : e~1 /1 2and 1130 ofthe maximumreCllm mendeddailyinlranasal doseinadults andchildren onamcg/m'basis,respecliveM· Nomutagenicllystudi eswith triam cinolone acetonide havebeenpertermed. . Inmaleandfemale rats,triam cinolene acetonidecaused nochangeinpregnancy ratealoral doses up to15.0m cglkg( a p p ro Xi ma t e~t/2 efthemaximum recom mendeddailyintranasaldese inadulls onamcg/m' basis).T riamcinoloneacetonide causedincreased fetal resorpliens andsti ll birt hsand decreasesinpupweightand survival atdeses015.0mcglkgand above (approxi malely 115 ofthe maximum recommended d aĩ intranasaldese in adulls on amcg/m' basis).At 1.0 mcglkg( ap p ro xi m at e~1130oflhem aximum recommendedd 3l~m tranasal dose inadullson amcg/m' basis),it didnotinduce theabovemenlionedeffects. Pregnaney: TeratogenicEffects: PregnancyC ategoryC .Triamcinolone acelonide ,~s teratogenicinrats, rabbits, and monkeys. In rats, triam cinoloneacetonide was teralogenical inhalationdosesof20m c~~g and above l app r o xi m a l e~7110 of themaXImum recommended daĩ inlranasal dese inadulls on am~/ m ' basis).Inrab~ns , triamci nelone acetonide was teratogenicatinhalation doses01 20mcglkg and above l a p p r ox i m a t e~2tim es the maximum recommended da i~intranasal doseinadullson amcg/m' basis).Inmonke.ys, .l r~mcino l one acelonide waslemtogenicalaninhalation dose of500 mcglkg ( appre xi m a t e~37 times tfle maximum reCllmmendal d 3l~m tranasal dose inadullsonamcgJrn' bas~) . Oose-retated temtogenieeffects inratsand mbbrts inclulred clert patate andlerint emal h yd rocepha~and ax~1 skeletal detects,I' ,tereastheeHects observed inthe monkeywere cmnial mallormations. There are noadequateand well -eontroHed st udies inpr egnant women.Therefere,t r~mci no l o n e acelonide should be usedinpregnancy onĩ fthe potential benelltjustifies the potent ial nsktothefetus.Since theirintroduclion, experience wfih eral corticosteroids inpharmacologicas opposed tophysiologicdoses suggests that rodents are more prone tolemtogeniceHects from cort i co~e ro i ds thanhumans. In addITion, because there isanatuml increaseinglucocorticoidproduction dunng pregnancy, most women I' nll require alower exogenous corticosleroiddose andmany v,ill not needcorticosleroidtreatmentdunng pregnancy. NonteratogeoicE ffecls: Hypoadrenalismmay occur ininlants bern ofmothe~receMngcortiCllsteroidsduringpregnancy. Such infant s shou l d b ecarefu l~observe d.
. . . Nursing Molfrers: II isnet known whelherIriamcineloneacetonideisexcretedin humanm ilk. Because Olher cort icosterOids areexcr eted 10 humanmilk, caut ionshouldbe exercisedwhenNasacort AD Nasal Spmy isadministered tonursi ngwomen, PediatrieUse: SafetyandeHectivenessinpedialricpatients b. elowtheageof 6yearshave not beenestablished. . C ert icosteroidshave been shown tocause grOY,1hsuppresslcn 10 c h l l dr en a ndt ee nagers ,p a r t l cu l ar~w i t hh l gher doses ov e r e~e nd edpe n eds . I f achi l d orf eena geronanycert i co st er oi d a p pears t o havegrov~hs u ppr e s si e n , l h e pe ssl b i l i t yt f l at t h ey a r e p a r t i cul ar~sen sni ve t ot hi seHect ofcorticosteroids should be considered. ADVERSEREACTIONS Inplacebo-conlrolled,double-blind,and epen-Iabel clinical sl udies,14B3 adults andchildren12 years andolder receivedtreatment wnh I r~m ci no l o ne acetonide aqueous nasalspray.These palents were tret.edlor an avemge duration of51days.Inthecontronal t r i a~(2-5weeks duration) fremI' ,tich Iteloll ol ',ing adveffiereact iondata are derived, 1394 pat~nt s were treatedwith NasacortAD Nasal Spm yleranavemge of 19 days.Inalong-term,open-tabel study,172 patients received treatment for an average duration of 2B6 days.
Adverse eventsoccurringat an i n~d en ce of 2%orgreater and more Cllmmonamong Nasacort AD-treatedpatients than placebe-treated p a t i e nt s i nco nt r o l i edad u l i c l i n i ca l t r~l s we r e : Nasa·"".~( triarrrinoione acetonide) For lotraoasalU seO oly Shake W ell BeloreUsiog BRIEFSUMM ARY CONTRAINDlCATI ONS Hyperseosnivityto aoy ofthe ingredieots of thispreparatioo cootraindicates nsuse. WARNINGS Thereplacemeot of asystem iccorticosteroidwnh atopical cMicoid can be accom paoiedby signs ofadrenal iosufficieocy aDd. io addnion, som epatients may experieocesymptoms of withdrawal,e.g..joiot aodlormuscular pain,lassnude aDd depression.P atieotsprel10usly treated torprolonged periodswrth syslemic coruco~eroi d s andtmosferredto topicalcorticoids should 00 caref ul moortoredlor ac~e adreo~msufficleocy io response tostress.10 those palienlswho haveasthmaorothercl inicalcoodITioosreQuiringloog·termsystemiccorticosterOIdtreatmeo!. too rapidadecrease insystemic corticosteroids maycause asevereexacerbatioooftheirsymptoms. Childreo w l 10are on im m urmsuppressantdrugs are more susceplbl e toiofecloostflan heal' J1y ch ĩren . C hickenpox and measles,fa, exampl e,can have amore serious or even fatalco u~e iochĩr eo on ",munosuppressant doses ofcorucosteroids.10 such children, orinadults 1' ,tO have Dot haJj tIlesed'seases,particular care should 00 taken toavoid exposure. II exposed,ther2llY wrth Ĩ nee l l a-z~t er ",mune g!obulin(\'ZIG)orpooled i nt m~i l OU s L1UTIunog' obufm IMG ),asapprop~~, may be indicated. II ch~kenpox develops,t..meot I ' , f~al'tiviIaI agents may 00 considered. The use 01 Nasacort Nasal lnha!er wnh allernate-daysystem icprednisonecouldiocreasethe likelihood ofhypotflalamic-pltuitary-adr eoal (H P A ) suppressioo compared toatfl erapeut icdose ofeitfler one alone.Therelore. Nam ort Nasal lnllaler shouldbe usedv.~h cautionin patienlsalreadyreceMngallernate-dayprednisone treatment for any disease. PRECAUTIONS G eneral:Incl inical studies wnh tnamci nol one acelonide adm inistered i ot r a na s al~, the development oflocaliz edinfectionsoftfle noseand pharynx I' .ithCandida afbiCJns has mre~occurred. \ ' ,~ea such an i n~e ct i o n develops, nmayrequire treatmenl I', ithappr opr~te local Iterapy and disCllntinuance oftreatmentI\ithNasacortNasal lnhaler, Triamcinoloneacetonide administered i n t r a na s a l has been shovm fa be absorbedint oIhesystemicci rculationinhumans. Palients wilh active rhinnisshowed absorptionsimilar tothat found innormal volunteers. Nasacort al 440 mcg'dayfor42daysdid not measumblyaHect adrenal response toasixhourcosyntropinlest. Inthe same study, prednisone 10 mg/day s i g n I T i cant~reduced adrenal responsetoACTH overthesame period Isee C LINICAl TRIALS section). Nasacort Nasal lnhalershouldbe usedwnhcaution, ITa t all, inpatieots wITh active or Quiescenttuberculous infectionsofthe respiratory tractor in patieotswnhuntreatedfungal,bacterial,orsystemicviral inlections orocularherpes simplex. Because ofthe inhibITory effect of corticosteroidson woundhealing inpatients who have experiencedrecent nasal septal ulcers, nasal surgery ortrauma, acorticosteroidshouldbeusedwnh caution until healinghaseccurred. As wilh other nasally inhaled certicesteroids, nasal septal pert orationshave been reperted inrare instances. IVhenused atexcessive doses,systemiccerticesteroideffectssuch as hypercort icism and adrenalsupp,ession may appear.Ifsuchchanges occur,Nasacort Nasal Inhalershould be discontinued sl ow~, consistent wnh accepled procedures fordiscontinuing oral steroid thempy. loformalionforPalieots: Palients being trealed wnh Nasacort Nasal Inhaler shouldreceive the foll ol 'nng inlormationand instructions. Patients 1' ,tO areon immunesuppressant doses ofcorticosteroids shouldbe warned1 0avoidexposure tochickenpoxermeaslesand, IT exposed,toebtainmedical advice, Patients shoulduseNasacortNasal In haler alregular intervalssince nseffectiveness depends onfi sregular use.Adecrease insymptoms may occur as sean as 12 h o u~aterstarting steroidtherapyand g enera l~can be expected tooccurwnhinafewdays 01inI Tiati ngtherapy in a~erg~rhinitis. The patieot should take themedicati onas directed and s ho u~not exceed tfl eprescnbed cosage.ThepateD! should Cilntaa tfle physician ITsymptoms do not im provearter three weeks, orif Itecendltionworsens. Nasal irr rt alion andlor bur Ding or st lOglOg arter useoftfle spmy occur o n~m r e~w fi hthisproduct. The patient shouldcontact the physician ITtheyoccur.
. . . forIteproper use ef thisunn and toattain maximum improvement. thepatieot shouldread and foll ow theaC Cllmpanying patient IOstructrons carel ul, S p m~n g triamcinolene acetonide dire~ontothe nasat septum shouldbe aVlliced.BeCJusethe amountdispensed per puff may not be consistent. il isimportant toshake the canister well .AJso,the canistersheuldbe discardedarter l00 actuatiens.
Ca~i n oge~, MJrtagfnesis: No ",dence ol t re. 1I neot -re led cartinogen~was demoDmled afler2years ofonce da ĩ gavage administra' jon ef~m~n ol o n e aeetonide atdeses of0.05,0.2 and1.0mC!l1<g{ approxi mat e~0.1 ,0.4and 1.8%of tfl ereCllmmended chnical d~e on amcgJm' basislinthe m tand 0.1 ,0.6 and3.0mC!l1<g( a p p ro x i ma l e~0 .1,0.6 and3.0% oftfle reCllmmendedcllnicatdese enamcg/ m' basis) in the meuse. Mtrtagenesisstudies wilhlriamcinelone acetonide have not been conducted. Impairmenl of Fertility: Noevidence of impaired fertility wasdemonstratedwhen oral doses up to15mcglkg (approximately28%of the recom mendedclinicaldeseonamcg/m' basis)wereadministeredtofemaleand male rals.Hewever,triamcinolene acetonide atoral deses of B.O mcglkg ( a pp rox i mate~15.0%ef the recemmendedclinical dose onamcg/m' basis)caused dystocia and prolenged delivery and at eral deses of5.0m cglkglapproximalely9.0%oftherecemmendedcl inical dose en amcg/m' basis) and aboveproduced increases inlelal resorptiens andsl illbir1fJs as well as decreases inpup body weight andsurvival.AI aD eral dose 01 1.0mcglkg (approximately2.0%ofthe reCllm mended cl inical dese on amcg/m' basis),fidid not manifest the above menlioned eHects. Pregnancy: Pregnancy CalegoryC _T riam ci noloneac~on i de was temtogen~ali nh~ati ona l doses of20,40 and BO mc~~g inrats ( a pp roxi m a l e0 .4,0.T5 and1. 5times the recommenced cl inical dose onamcg/rn' basis,r espe ct i ve~) andmbbits l a p pr ox i m a l e~0.7 5,1.5 and 3.0 ti mes the recemmended dese on amcg/rn' basis, r e s p e ct i v e~) . Tr~mc i no l ene acetonide was alsoterategenicat an inhalati onal dose of 500 mc~~g inmonkeys l appre x i ma t e~1Btimes the recommended ct inical dose en amcg/m ' basis).O ose-related teralogeniceffects in rats andrabbITs included clert patale,int ernalhydrocephaly,and ax~1 skeletal defects.T eratogeniceffectsobservedintfle monkeywere CNS and cranial malformations.Thereare no adequate and well-eontrolled sludies inpregnant women.Triamci nolone acetonide shouldbe used dunngpregnancy on~ITthepotentia l benefITS j us~the potential risk tothefetus. Experience wfih oral C O rt iCllidssince theirintroduction inpharmacologicas opposed tophysiologicdoses suggests thatrodenlsare more plane totemtogenic effects from c er t~o i cs tflan humans. In addI Tion, because th ereisanatural increase ingluceCllrticoidprodtlClion dunng pregnancy, mostwomen vnll reQuire alowerexogenoussleroiddose and manyI' nl i not need corticoidIreatment during pregnancy. Nontemtogenie E ffecls: Hypoadrenalism may oceur ininfanls born 01 mothm receiving corticosteroids dunng pregnancy. Such infants sh eul d b e ca r e l ulo b se rv ed , N u~i ng Mothers: It isnot known whelhertriam cinoleneacetenideisexcretedinhuman milk. Becauseother certicosleroids are excreted inhuman m ilk,cauti on shouldbe exercised when Nasa cort Nasal Inhalerisadministered 10 nursing women. Pedi~r i c Use:S a f~ande ff ect iveness inpediatricpalient sbelowtheage of6have notbeenestablished.Oral corticosleroidshave beenshown to causegrowth suppressionin childrenandleenagers,particularly wfi hhig h e r do ses o v e r e~e nd e d p e r i od s . l l a c h i l d or l ee n a g e r on a n Y Cl l r t l c0 st eroi dap pe arstoh avegrov~h suppr essi o n , tfl epossibility tflat they are parucularly sensnive 10 thiseffect elsteroids sheuld 00 considered. ADVERS EREACTIONS Adults aDdC hildren12years ofage andolder:Incontrolled and uncontrolled sl udies, 1257adult and adolescent patients received trealment I'nthinlranasal tr~mc i n o l one acelonide. Adversereactions are basedon the567palientswho received apr oduct similarto the markeled Nasacortcanister. These patients were Ireatedfor an avemge of 48 days (mngeIto117 days).The 145 patents enrolled inuncontrolled studiesrece,' ed beatment from I to820 days (avemge332 daYSI.Themost prevalent adve~e expenence v .~s headache, being reported byapprox i ma t e~l B %ofthe patients v,torecer,ed Nasacort_Nasal irritationViasreported by2.B%ofthe patients receMngNasacort, Other nasepharyngeal side eH ects were reported byfewer than 5%of tIepati ems who received Nasacert and included: dry mucousmem branes,naw-sinusCllngesti en,Itroat discomfort, sneezing, and epistaxis. The comptaints donO I u su a l int enerewfi htreatmenl and inthe cont rolled and unconlrolled st udies appro xim~e~1%01 pat~ots have discontinued because 01 thesenasal a dve~e efects. In the evenl of accidental overdose, anincreased poteotiallor Ihese adve~e experi ences maybe expected,but slSlemicadverse eXp'nences are u nl i ke~(se eO VEROO S AGEsect ion). C hildreo6through 11years of age:Advmeeventdata inchildren 6through 11 years01age afe derived from two cont rolled clIOicalt r~l s of tva and four weeks curation. lnthese trials, 127 patients received fixed doses of220 mcg/dayeftri amcinoloneacetonide lor aD average ef22days(rangeBt033days). Adverse eventseccurnngat anincidence of3%orgreater and more common among childrentrealedwnh 220 mcg triamcinolone acetonide tive syndrome. The leukocyte alkaline phosp hatase level was eleva ted. The hematoma grad ually regressed and was significan tly sma ller on CT after 7 days . Blood analysis sugges ted polycythemia vera.
Case 2
A 30-year-old woman came to our emerge ncy roo m co mplaining of a cold of 15 days' duration. Her neck had begu n to ache the previous day, and she exper ienced odyno phagia associated with submandibular and cerv ical swelling that had progressed rapidly. The patient had hemoptysis and denied dysp nea and dysphonia. She also denied any trauma or tobacco or alco hol abuse.
On phy sica l exa mination, the woman was icteric. She also exhibited submandibular and anterior cerv ical swe lling (figure 2) and ecchymosis, as well as ecc hymosis in her legs. Inspection of her oral cav ity revea led edema and hyperemi a of the uvula and soft pala te, and her posterior phary ngea l wall was displaced. Abdominal exa mina tion revealed collate ral circ ulation, asci tes, and an enlarged liver and splee n.
Aga in, we initi ated treat ment while awaiting laboratory results, which revealed a hemoglobin level on.3 g/dl and a hematocrit of 24%. The aspartate aminotransferase was 37, the alanine aminotransferase was 58, the thrombin time was 23 (16 ±2), the pro throm bin time was 41, and the partial thromboplastin time was 58 (35 ±4). Our suspicion of cerv ical hematoma was confirmed by CT ( figure 3 ). The hematoma was absorbe d in 10 days. Portal hypertension and schistoso miasis were diagnose d, and treatm ent was introduced. Five days later, she presented again with upper diges tive h emorrhage caused by esop hageal varices .
Discussion
Cervical hematoma is a rare .conditio n. Its primary causes are trauma, infection , great -ves sel inj ury, foreign- body ingestion , and cervical spine inj ury. There are also reports of cases related to anticoag ulation therapy and polycythemia vera. 1, 2 Sympt om s may include hoarseness, dysp nea, and dysphagia. Physical exa mination reveals swelling in the anterior aspect of the neck, respiratory distress, and, in severe cases , neck tenderness.' Radiologic exa minatio n may show an impairment of airway colurnn.P
The muscles of the neck are enclose d by layers of fibro us connective tissue. These layers fuse to form the cervical fasc ia. These layers determine cervi cal compartments that form a pathway along which hematomas spread .' In some cases, these spaces fill with purulent secretio ns (as in cervica l abscesses) or with blo od (as in hematomas Due to the different amoxicillin to clavulanle acid ratios in the Augmentjn 250 mg tablet (250 /125)versus tha Augment in250mgchawablatablat(25O/62.51.tha Augment in250mgtablet shouldnot be usaduntil tha padiatric patient weighs at least 40kg or mora. Hepatically imp airedpatients should bedosedwith cautionand hepatic function monitored at regular intervals. (SeeWARNINGS.I Administration: Aug mentin may be taken without regardto meals; however. absor ption of c1avul anate potassiumis enhancedwhen Augmentinis administered at thestart of a meal. To minimizethepotential for gastrointestinal intolerance. Augmentin shoul d betaken at the stanof a meal. BRS·AG:AL5/PL5A evi dence of harm to thefetusdueto Augmentin. There are, however, noadequate and well -cont rolled studies in pregnant women. Becauseanimalreproduction studiesarenot always predictive of human response. usethisdrug during pregnancy onlyif clearly needed. LaborandDel iYery: Oral ampicillinclassantibiotics aregenerallypoorly absorbed during labor. St udies in guinea pigs haveshown that intravenous admi nistrationof ampicillindecreased theuterine tone, frequency of contractions. height of contractions and duration of contractions. However, it is not known whether the use of Augmentin in humans during labor or delivery has immediate or delayed adverse effects onthefetus. prolongs the duration of labor. or increases the likelihood that forceps del ivery or other obstetrical intervention orresuscitationof thenewborn will benecessary. NursingMothers: Ampicillin classantibioticsareexcreted inthemilk; therefore, caution should beexercised when Augmentin is administered to a nursing woman.
Pediatric Use: Incompletely developed renal function inneonates and young infantsmay delay theelimination of amoxicillin. Oosing of Augmentin should be modified in pediatric patients younger than 12 weeks (3months). (See DOSAGEAND ADMINISTRATION-Pediatric .) ADVERSE REACTIONS: Augmentin isgenerally welltolerated. The majority of sideeffects observed in clinicaltrialswere mildand transient <3%of patients discontinued therapy becauseof druq-related side effects. From theoriginal premarket ingstudies. where both pediatric andadult patients were enrolled. the most frequently reponed adverse effects werediarrhea/loose stools (9%1 . nausea 13%). skin rashes and urticar ia 13%1. vom iting11 %)and vag initis11%1. The overall incidence of sideeffects. and in particular diarrhea. increasedwiththe higher recommended dose. Otherlessfrequently reponedreactions include: abdominal discomfort. flatulence and headache. Thefollowingadverse reactions have been reportedforampicillinclass antibiotics: Diarrhea,nausea.vomiting, indigestion, gastritis,stomatitis,glossitis, black "hairy" tongue.mucocut aneous candidiasis. enterocolitis,and hem orrhagic/pseudomembranouscoli tis. Onsetof pseudomembranous coli tissymptoms may occur during or after antibiotic treatment. ISee WARNINGS.) Skin rashes. pruritus. urticaria. angioedema, serum sickness-like reactions (urticaria or skin rash accompanied by arthritis, anhralgia.myalg iaand frequently fever).erythema mul tiforme (rarelyStevens-JohnsonSyndromel andan occasi onal case of exfoliative dermatitis (includingtoxi c epidermal necrolysis). These reactions may be controlledwithantihistaminesand,if necessary, systemiccorticosteroids. Wheneversuchreactionsoccur, thedrug shouldbediscontinued. unlesstheopinionofthephysi ciandictates otherwise. Seriousandcecasional fatalhypersensitivity lanaphylactic)reactions can occurwith oral penicillin. (See WARN INGS.)A moderate rise in AST(SGOTI and/or ALTISGPT) hasbeen noted in patients treated with ampicillinclass antibiot icsbutthesi gnificanceof these findings is unknown. Hepatic dysfunction. including increases in serumtransaminases(ASTand/ or AL T). serumbilirubinand/or alkal ine phosphatase. hasbeen infrequently reponedwith Augmentin. It has beenreponed more commo nly in theelderly. in mal es. or in patients on prolonged treatment. The histologic findings onliverbiopsy have consisted of predominantl ycholestatic, hepatocellul ar. ormixedcholestatic·hepatocellularchanges. Theonset of si gns/symptomsof hepaticdvsfunctionmay occur duringorseveral weeksaftertherapy has been discontinued.The hepatic dysfunction. which may besevere. is usually reversibl e. On rare occasions. deaths have been reponed (lessthan 1 death reponedper estimated4 milli onprescriptions worldwide). These havegenerally beencases associatedwith ser iousunderlying diseases or concomitant medications. Interstitial nephritis and hematuria have beenreponedrarely. Anemia.including hemolyticanemia. thrombocytopenia. thrombocytopenicpurpura. eosinophilia. leukopenia andagranulocytosis have been reponed during therapy with penicillins. Thesereactionsareusually reversibleondiscontinuationof therapy and arebel ieved to be hypersensitivity phenomena. A slight thrombocyt osis wasnoted in less than 1% of the patients treated with Aug· Due to incompletely developedrenal functionaffecting amoxicillin eliminationin this agegroup. the rec-ommendeddoseofAugmentin is30 mglkg/day. dividedq12h. basedontheamoxicillincomponent. Clavu· lanate elimination isunalteredin thisagegroup. Experience withthe200 mg/5 mL formulation inthisage group is limited. and thus. use of the125 mg/5 mLoral suspension is recommended. Augmentin use is usually reversible. On rareoccasions. deaths havebeen reponed(less than 1deathreo ported perestimated4millionprescriptionsworldwi de). Thesehave generally been cases associatedwith serious underlying diseases or concomitantmedi cat ions. ISee CONTRAINDICATIONSand ADVERSE RE· ACTIONS.) PRECAUTIONS: Ganaral: While Augmentin possesses the characteristic low toxicity of thepenicillin group of antibiotics. periodi c assessmentof organ systemfunctions, includingrenal. hepatic and hematopoieticfunction. is advisable duringprol onged therapy. A high percentage of patients with mononucleosis who receive ampicillin develop anerythematous skin rash. Thus. ampicillin class antibioticsshould not beadministered to patients with mononucleosis. The possibility of superinfect ionswith mycotic or bacteri al pathogensshould be keptin mind during therapy. if superinfections occur lusually involving Pseudomonas or Candidal. the drug should be discontinued and/or appropriate therapy instituted. Information for tha Patient Augmentin may be taken every Bor 12 hours. dep endingonthe product strength prescribed. Eachdoseshould be taken with a meal or snack to reduce the possibilityof gastrointestinal upset. Manyantibiot icscan cause diarrhea. If diarrhea is severe or lasts more than 2 or3 days. call your doctor. Be sureyour child completes theentire prescribedcourse of treatment. even if he/she begins to feel better after a few days. Keep suspension refrigerated. Shake well beforeusing. When dosinga child withAug mentin suspension{liquid}. use a dosing spoon or medicine dropper.Rinse the spoon or dropper after each use. Bottles of Augmentin suspension may contain more liquid than required. Foll ow your doctor's instructionsabo ut the amount to useand thedays of treatmentyour chil d requires. Di scard anyunused medicine. Phenylketonurics: Each 200 mgAugmentin chewable tablet contains2.1 mgphenyl alanine; each 400 mg chewable tabletcontains4.2mgphenylalanine ; each 5 mLof either the200mg/5mLor400 mg/5 mL oral suspensioncontains 7mgphenylalani ne. OtherAugmentin productsdonot containphenylalanineand can be used by phenylketonurics. Contactyour physicianor pharmacist. Drug Interactions: Probenecid decreases therenal tubular secretion of amoxicillin. Concurrent usewith Augmentin may result in increased and prolonged blood levels of amoxicillin. Co-administration of probenecid cannot berecommended. The concurrent administrationof allopurinoland ampicillinincreases substantially theincidence of rashes in patients receiving both drugs ascompared to patients receiving ampicillin alone. It is notknown whether thispotentiation of ampicillinrashes isdueto allopurinol orthe hyperuricemia present in these patients. There arenodatawithAugmentinand allopurinoladministered concurrently. In common with other broad-spectrum antibiotics. Augmentin may reduce theefficacy of oraleontraceptives. Drug/Laboratory Tast Interactions: Or al administration of Augmentinwill result in high urine concentrationsof amoxicillin. High urineconcentrationsof ampicillin mayresult in false-positivereactions when testing for the presence of glucose in urine usi ng Clinitest'. Benedict's Solution or Fehling's Solution. Sincethis effectmay also occur with amoxicillin andthereforeAugmentin,it is recommended that glu· case tests based on enzymatic glucose oxidase reactions(such asClinistixeorTes·Tapee) be used. Following administrationof ampicillin to pregnant women a transientdecrease in plasma concentration of total conj ugated est riol. est riol -glucuronide. conjugated estrone and est radiol hasbeen noted. This effect may alsooccur with amoxicillin andthereforeAugmentin .
Carcinogenesis. Mutagenesis,'Impainnent of Fertility: l ong-termstudies in animals have notbeen performed to evaluate carci nogeni c potenti al.Mutaganasis: Themutagenic potential of Augmentinwas investigated in vitrowithanAmes test. a humanlymphocyt ecytogenetic assay. ayeast test and a mouse lymphomaforwardmutationassay, and invivo withmousemicronucleustestsanda dominant lethaltest.
All were negative apan fromthe in vitromouse lymphoma assay where weak act ivitywasfound at very high, cytotoxicconcentrations. Impairment of fertility: Augment in at oraldoses of up to 1200 mglkg/day15.7 times the maximum human dose. 14BOmg/m'/day. based onbody surfacearea) was found to have no effect on fenility and reproductive performance in ratsdosed with a 2:1ratio formu lationof amoxicillin:clavulanate. Teratogenic affacts: Pragnancy (Category B): Reproductionstudiesperiormedin pregnant rats and mice given Augmentin at oral dosages up to 1200 mg lkg/day. equivalent to 7200 and4080 mg/m'/day. respectively(4.9 and 2.8times themaximum humanoral dose basedon body surface area). revealed no SPONTANEOUS CERVICAL HEMATOMA: A REPORT OF TWO CASES other and with the mediastinal spaces. This communication favor s the spread of hematomas that can lead to airway or great-vess el compression . The communication of the peripharyngeal and carotid space explains subcutaneou s ecchymosis.
In the two cases we describe, both patient s experienced an extensive spontaneous cer vical hematoma. The male patient had polycythemia vera and othe r co agulation disorders cau sed by portal hypertension ; he also had hep atop athy , probably caused by the schistosomiasis. Neith er patient had upper airw ay obstruction.
Th e distortion of the hep atic architecture in chr oni c hep atopathies lead s to a marked incre ase in resistance to portal venous flow , which in turn lead s to an increase in portal venous pressure. The primary clinical manifestation s are hemorrhage due to esoph ageal varices, splenomegaly , ascites, and hep atic enc eph alopathy. Schistosomiasis caused by Schistosoma mansoni can involve the liver, and infiltrating granulomas can result in hep atopathy. Coagulopathy is one of the primary con sequences. The live r synthesizes factor V, fibrinogen, plasminogen , and factors XI and XII. Any deficiency ofthese factorsthe vitamin-K-dependent facto rs-leads to coagulopathy, which can cause hem atom as and ecchymosis. We did not find in the literature any other ca ses of cervical hem atomas that were associated with liver disease. There are reports of cervical hem atomas in patients who were undergo ing anticoagulation therapy; the most common form s are laryn geal , retropharyngeal, and sublingual.F Polycythemia vera is a dise ase of unknown origin ; it is manifest by an absolute increase in the number of red blood corpuscle s and total blood volume. Spontaneous thrombosis is easily explained by an increase in blo od viscosity and the number of platelet s, as well as by a trend to stasis. Paradoxically, patients with high numbers of platelets can also experience spontaneous hemo rrhag e. (The platelet count in our 81-year-old male patient was normal.)
The diagnosis of poly cythemia vera describ ed in case I was based on five criteria : the pre sence of splenomegaly and leukocytosis and the high level s of erythrocyte s, platelets, and leuko cyte alkal ine pho sphatase.v"
The literature reports only a few cases of spontaneous bleeding in patient s with polycythemia vera.t" One of these cases occurred in a 72-year-old patient who had a retropharyngeal hem atoma. " Poly cythemia frequently presents as a thrombotic complication, although a bleeding tendency is noted and its precise cause is unknown. " :" Some authors suggest that it may be caused by abnormal platelet function." :" Oth ers sugge st the existence of a fibrinolyti c factor.'?
As with many of the head and neck diseases, treatment begins with the management of the upper airway. Some rese archers suggest performing a tracheotomy in the case of obstruction, believ ing that orotracheal intubation may be dangerous because of the risk of rupturing the he-Volume 78, Number 3 matoma and the con sequent aspiration. ' The management of the hem atoma itself is controversial. Very few resear chers suggest surgical drain age. Mo st prefer to wait for natural absorption , except when the hematoma progresses to other deep neck spaces or involves the uppe r airway; in these cases, surgical drainage is indicated.P The hem atoma will usually resolve in 2 to 4 weeks.
Despite their size, the two hematomas described in thi s repo rt did not lead to upper airway obstructi on or to compression of the neuro vascula r structures. We decided to initiate conservative management with proph ylactic antib iotics rathe r than perfo rming surgical drainage becau se of the potential complications of the latter , such as contamination and bleeding. Both patients responded well and fully recovered in 2 weeks.
